1Q EARNINGS: Celgene boosts sales, bets big on Crohn's drug

Celgene's 19% year-over-year increase in first quarter net product sales was driven by hematology and oncology products, but alongside its January-to-March earnings report the company announced a $710m investment to diversify its portfolio and expand its fledgling immunology and inflammation franchise.